Back to News
Jan 12, 2026 8:10 AM

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Financing led by institutional investors, with participation from new investor Eli Lilly and Company

Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to date

Separately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix's discovery pipeline

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that it has completed an equity financing led by institutional investors -- including Access Biotechnology, Alexandria Venture Investments, NEA and Westlake BioPartners, alongside a strategic investment by Lilly.

The company also announced that it has been selected by Lilly to access Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new ...